Lumos Diagnostics Expands FebriDx® Use to Pediatric Settings with BARDA Support

The latest update is out from Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ).

Lumos Diagnostics Holdings Ltd. has announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to conduct a clinical study aimed at expanding the use of its FebriDx® diagnostic test to pediatric patients aged 2-12 years in CLIA-waived settings. This study, supported by a $6.198 million funding package from BARDA, is expected to significantly increase Lumos’ market reach by potentially expanding its U.S. total addressable market 15-fold to over $1 billion, providing access to 270,000 clinical sites and covering 80 million annual acute respiratory consultations.

More about Lumos Diagnostics Holdings Ltd.

Lumos Diagnostics specializes in rapid, point-of-care diagnostic test technology to aid healthcare professionals in accurately diagnosing and managing medical conditions. The company offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms, focusing on infectious and inflammatory diseases.

Average Trading Volume: 6,420,680

Technical Sentiment Signal: Buy

Current Market Cap: A$94.19M

Learn more about LDX stock on TipRanks’ Stock Analysis page.